Negative Research Results–Mostly Concealed in Journals_SharonBegley, WSJ
"Why are scientists coy about publishing negative data?
"Why are scientists coy about publishing negative data?
FDA's slip-shod approval of defective, harmful drugs, accompanied by rubber stampped endorsements by compromised FDA advisory committees may be reaching a boiling point.
The ethics of this radical drug experiment is being challenged by Dr. Jerald Block, a forthright psychiatrist and experienced system's analyst. His critical appraisal, published in the Bioethics Forum, Hastings Center Report.
Legislation is needed to ensure that conflicts of interest rules in medicine are enforced. One method for reigning in the abuse is to prohibit government grant awards to any researcher who violates financial conflict of interest rules.
Off-label prescribing of drugs for unapproved uses puts consumers at high risk of harm–but it is the single most lucrative marketing strategy.
Today's news report circulated by the media about the negative findings of a much touted, but uncontrolled observational study of depression (STAR*D) promotes the business interests of SSRI antidepressant drug manufacturers.
An Orwellian nightmare is being implemented on infants even as the evidence demonstrates that the psychiatry's practice guidelines are corrupted by
industry.
Business Week reports: "From 1986 to 2003 the number of nonsurgical cardiac procedures, such as propping open arteries with wire-mesh stents, rose twelve fold, according to the American Heart Association.
Medical researchers who commit fraud and research misconduct are caught only when a person of conscience steps up to the plate and blows the whistle. There are no systemic, independent checks and balances to prevent research fraud or abuse of patients.
AHRP Campaign to Protect Children from Harm Oct 15: FDA Orders Black Box Warnings on Antidepressants labels and Patient Information Guides to Warn about Suicide risk Oct 3: BBC PANORAMA TONIGHT – Taken on Trust – 13 years-Medical Deception Sep 30: GSK Sales Reps told NOT to Divulge Paxill Data…
Children in "Hot Demand" for Clinical Trials May 31, 2002 FYI Rachel Zimmerman of The Wall Street Journal reports about the "frenzy" to recruit children for drug trials. The inclusion of children in drug trials allows pharmaceutical companies to cash in on six month patent exclusivity extensions worth hundreds of millions of dollars….
Cymbalta Contract: How Eli Lilly Influences What Prescribers Learn about Lilly’s drugs Fri, 5 Aug 2005 The Wall Street Journal reports that not only do drug manufacturers control what the public is told about patented drugs, but companies, such as Eli Lilly and Pfizer dictate by contract what doctors are…